ReviewLife (Basel, Switzerland)2025
Current Progress in Peritoneal Dialysis: A Narrative Review of Progress in Peritoneal Dialysis Fluid.
Review in Life (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Therapeutic potential of amino acid-based peritoneal dialysis solutions: a systematic review.BMC nephrology · 2026Pooled it
- Multi-Omics Analysis of PBMCs Revealed Distinct Biological Differences Between Hemodialysis and Peritoneal Dialysis.International journal of molecular sciences · 2026Article
- Preserving residual kidney function in peritoneal dialysis: from conventional approaches to contemporary practice.Clinical kidney journal · 2026Review
- [Mesothelial impairment induced by peritoneal dialysis and its potential protective strategies].Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2026Review
- Effect of peritoneal dialysate on peritoneal fibrosis.BMC nephrology · 2026Article
- Management of Hypertension in Patients Undergoing Peritoneal Dialysis: A Narrative Review.Cureus · 2026Review
- Molecular biomarkers in dialysis-related thrombosis and anticoagulation monitoring: thrombin-antithrombin complex, plasmin-α2-antiplasmin complex, soluble thrombomodulin, tPA/PAI-1/tPAIC, and Anti-Xa.Frontiers in medicine · 2026Review
- Innovations in peritoneal dialysis fluid: biocompatible formulations and expanded therapeutic applications.Renal failure · 2025Review
- Hidden Impacts of Peritoneal Dialysis on the Endocrine System.Life (Basel, Switzerland) · 2025Review
- Elevated effluent lactate independently predicts the adverse outcomes of peritoneal dialysis associated peritonitis.Scientific reports · 2025Article
- Remote Patient Monitoring in Home Dialysis Patients: Enhancing Care for Home Hemodialysis and Peritoneal Dialysis.Seminars in dialysisReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peritoneal dialysis (PD) is a renal replacement therapy that removes solutes, electrolytes, and water via the infusion of dialysis fluid into the peritoneal cavity. However, the non-physiological composition of conventional PD fluids can cause peritoneal injury, leading to complications such as peritoneal fibrosis and encapsulating peritoneal sclerosis. This review highlights recent advancements in PD fluid formulations aimed at improving biocompatibility and reducing peritoneal damage. While glucose-based solutions remain the standard because of their affordability, their glucose degradation products (GDPs) and advanced glycation end-products significantly contribute to peritoneal fibrosis. Innovations, such as neutral pH and low-GDP solutions, have been developed to counter these effects, enhancing peritoneal integrity and preserving residual renal function. Alternative osmotic agents, such as icodextrin, offer superior ultrafiltration. Advancements in buffer formulations, including bicarbonate-based and bicarbonate/lactate combinations, have further enhanced the biocompatibility of PD fluids. Despite these progressions, challenges persist. Therefore, future research should prioritize patient-specific PD solutions to optimize long-term outcomes and minimize adverse effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.